Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forma Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Technology platforms aren't in vogue these days. Many companies who took that route have since scaled back investments in their platform technology to concentrate instead on pipeline candidates. Forma Therapeutics thinks it can buck that trend. The company, founded in March 2008, is betting on a platform that features a chemical synthesis approach, called Diversity Oriented Synthesis (DOS), which can rapidly produce a large variety of chemical structures that have structural complexity similar to chemicals isolated from natural products, such as plants or corals reefs. Most automated synthesis platforms produce simpler chemical structures, but the large intricate, structures found natural products have long been a mainstay of pharmaceutical drug discovery efforts and gives the company access to unique structural space.

You may also be interested in...



Start-Up Previews (05/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Medical Dermatology Gets Under VCs' Skin," features profiles of Garnet Biotherapeutics, Medimetriks and Topica Pharmaceuticals. Plus these Start-Ups Across Health Care: Carolus Therapeutics, Forma Therapeutics, NovaLign Orthopaedics, OmegaGenesis and PercSys.

Start-Up Quarterly Statistics, Q1 2009

Highlights from the Q1 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $692 million--a 31% drop from Q1 2008 but a 25% increase from last quarter--with most of the money, $544 million, coming from the biopharma sector. There were no significant acquisitions of biopharma or in vitro diagnostic start-up companies in the first quarter of the year, but device giant Medtronic paid a total of $550 million for two start-ups. Cancer was the most popular therapeutic area for start-up alliances this quarter.

Start-Up Previews (05/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Medical Dermatology Gets Under VCs' Skin," features profiles of Garnet Biotherapeutics, Medimetriks and Topica Pharmaceuticals. Plus these Start-Ups Across Health Care: Carolus Therapeutics, Forma Therapeutics, NovaLign Orthopaedics, OmegaGenesis and PercSys.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091787

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel